UK markets close in 3 hours 32 minutes

Ion Beam Applications SA (IOBCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
11.130.00 (0.00%)
At close: 09:30AM EDT

Ion Beam Applications SA

3, Chemin du Cyclotron
Louvain-la-Neuve 1348
Belgium
32 1 047 58 11
https://www.iba-worldwide.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees1,668

Key executives

NameTitlePayExercisedYear born
Mr. Pierre MottetChairman of The Board52.92kN/A1962
Mr. Olivier LegrainCEO, Pres, MD & Exec. Director867.37kN/A1968
Mr. Yves JongenFounder, Chief Research Officer, MD & Exec. Director577.38kN/A1947
Ms. Soumya ChandramouliChief Financial OfficerN/AN/A1979
Mr. Frederic NolfChief HR & Sustainability OfficerN/AN/A1973
Olivier LechienCorp. Communication DirectorN/AN/AN/A
Mr. Matthias Dierl Ph.D.Chief Medical Physicist of Radiation TherapyN/AN/AN/A
Marc Van der BurghtExec. VP of Proton Therapy InstallationN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Corporate governance

Ion Beam Applications SA’s ISS governance QualityScore as of 1 October 2022 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.